Enteral Glutamine Administration in Critically Ill Nonseptic Patients Does Not Trigger Arginine Synthesis

Mechteld A. R. Vermeulen,1,2 Saskia J. H. Brinkmann,2 Nikki Buijs,2 Albertus Beishuizen,3,4 Pierre M. Bet,5 Alexander P. J. Houdijk,6 Johannes B. van Goudoever,7,8 and Paul A. M. van Leeuwen2

1Department of Internal Medicine, VU University Medical Center, 1081 HV Amsterdam, Netherlands
2Department of Surgery, VU University Medical Center, 1081 HV Amsterdam, Netherlands
3Department of Intensive Care Unit, VU University Medical Center, 1081 HV Amsterdam, Netherlands
4Intensive Care Unit, Medisch Spectrum Twente, 7511 JX Enschede, Netherlands
5Department of Clinical Pharmacology and Pharmacy, VU University Medical Center, 1081 HV Amsterdam, Netherlands
6Department of Surgery, Medical Center Alkmaar and Trial Center Holland Health, Alkmaar, Netherlands
7Department of Pediatrics, VU University Medical Center, 1081 HV Amsterdam, Netherlands
8Department of Pediatrics, Emma Children’s Hospital, AMC, 1105 AZ Amsterdam, Netherlands

Correspondence should be addressed to Paul A. M. van Leeuwen; pam.vleeuwen@vumc.nl

Received 24 October 2015; Revised 10 February 2016; Accepted 21 February 2016

Copyright © 2016 Mechteld A. R. Vermeulen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glutamine supplementation in specific groups of critically ill patients results in favourable clinical outcome. Enhancement of citrulline and arginine synthesis by glutamine could serve as a potential mechanism. However, while receiving optimal enteral nutrition, uptake and enteral metabolism of glutamine in critically ill patients remain unknown. Therefore we investigated the effect of a therapeutically relevant dose of L-glutamine on synthesis of L-citrulline and subsequent L-arginine in this group. Ten versus ten critically ill patients receiving full enteral nutrition, or isocaloric isonitrogenous enteral nutrition including 0.5g/kg L-alanyl-L-glutamine, were studied using stable isotopes. A cross-over design using intravenous and enteral tracers enabled splanchnic extraction (SE) calculations. Endogenous rate of appearance and SE of glutamine citrulline and arginine was not different (SE controls versus alanyl-glutamine: glutamine 48 and 48%, citrulline 33 versus 45%, and arginine 45 versus 42%). Turnover from glutamine to citrulline and arginine was not higher in glutamine-administered patients. In critically ill nonseptic patients receiving adequate nutrition and a relevant dose of glutamine there was no extra citrulline or arginine synthesis and glutamine SE was not increased. This suggests that for arginine synthesis enhancement there is no need for an additional dose of glutamine when this population is adequately fed. This trial is registered with NTR2285.

1. Introduction

Previously, numerous clinical studies demonstrated that supplementation with glutamine as free molecule or dipeptide results in a favourable clinical outcome as reflected by a reduction in infectious morbidity (trauma [1, 2] and medical [2–5] patients), mortality [3, 6], and a reduction in length of hospital stay in severely ill patients [4, 7–9]. However, the use of high dose glutamine in shock patients has been part of debate [10]. The underpinning mechanism of the clinical effects of exogenous glutamine administration has not been completely elucidated yet. The effects of glutamine could be partially explained by the substrate that glutamine is for the synthesis of citrulline and arginine. Citrulline may act as a radical scavenger and is also a potent arginine precursor [11]. Arginine is of great importance for wound healing and the immune system and it is the precursor of nitric oxide (NO) [12–16]. During trauma and sepsis, plasma concentrations of
arginine are decreased [17]. However, the action of arginine as a substrate for nitric oxide synthesis with potential subsequent hemodynamic instability and oxidative stress may be responsible for the reported adverse events of glutamine administration in severe critically ill patients [18–20]. Since endogenous glutamine can generate arginine by the citrulline pathway in the kidney, supplying glutamine may be a more physiologic and safe way to regulate arginine availability in the metabolically stressed ICU patient [21, 22]. However, in critically ill patients the metabolic fate of glutamine is still unclear. Possibly, generally altered metabolism could exist due to impaired enterocyte function because of injury, splanchnic ischemia, sepsis, and starvation.

Considering the observation that the gut preferentially takes up enterally provided glutamine, with subsequent higher intestinal release of citrulline, the precursor for arginine, we decided to provide L-alanyl-L-glutamine by the enteral route in this study, expecting to deliver glutamine most adequately to the interorgan pathway of glutamine into citrulline and arginine [23, 24]. Hence the objective of this clinical study was to investigate the effect of the enteral administration of a clinically relevant dose of L-glutamine, provided as L-alanyl-L-glutamine, on the synthesis of L-citrulline from L-glutamine and the subsequent synthesis of L-arginine from citrulline in critically ill nonseptic patients.

Quantitatively, tracer methodology was used to determine exact turnover of these amino acids. A cross-over study design using intravenous and enteral tracers was chosen enabling splanchnic extraction calculations. We hypothesized that after enteral glutamine supply splanchnic glutamine uptake would increase as well as subsequent increases in citrulline and arginine synthesis.

2. Patients and Methods

2.1. Patients. Twenty critically ill patients considered stable were studied. All were expected to stay at the ICU for at least 5 days. Additional inclusion criteria were age, ≥18 years, BMI ≥ 18.5 and ≤35, ability to tolerate enteral nutrition, provided by postpyloric tube, meeting full protein/energy requirements based on indirect calorimetric measurements, and a protein intake of 1.2–1.7 g/kg/day.

Exclusion criteria were septic shock (defined according to the International Guidelines for Diagnosis of Sepsis [25]); need for high dose vasoactive medication such as norepinephrine higher than 0.2 μg/kg/min; PaO₂/FiO₂ ratio < 200; PEEP > 15 cm H₂O; liver failure (bilirubin levels > 100 μmol/L); hyperammonaemia (ammonia > 50 μmol/L); kidney failure (renal replacement therapy or increase in serum creatinine levels to >100 μmol/L), in the absence of primary underlying renal disease, associated with oliguria (defined as urine output < 150 mL in the previous 8 hours); urea cycle defects; chronic corticosteroids use (>7.5 mg/day >3 weeks); gastrointestinal malabsorption possibly interfering with intestinal absorptive function (celiac disease, Crohn’s disease, presence of fistulas, major intestinal malabsorption disorder, or short bowel syndrome); pregnancy or lactation; admission after elective surgery; parenteral nutrition; use of medium chain triglycerides or glutamine/citrulline supplements.

Informed consent was obtained from all included patients or his/her legal representative. The Medical Ethical Committee of the VU University Medical Hospital approved the study protocol (METC VUMc 2009.083). The study complied with the Declaration of Helsinki (NTR2285).

2.2. Study Design. All twenty patients received enteral nutrition via postpyloric or nasogastric tube. Ten patients received an additional enteral dose of 0.5 g/kg/day L-alanyl-L-glutamine (ALA-GLN) (Fresenius Kabi Nederland B.V. Den Bosch, Netherlands). Patients in the control group received isonitrogenous enteral nutrition without the additional glutamine (CON). Total nitrogen was compensated by using different enteral nutritional formulas containing different amounts of protein. Patients were investigated while being fed continuously. The study protocol is outlined in Figure 1.

Resting energy expenditure (REE) was measured with the Deltatrac Metabolic Monitor (Datex-Engstrom Division, Helsinki, Finland), calibrated every day. Energy requirement
was measured within 24 h before study or control feeding was started. During measurements, nutrition was not interrupted. Body height and weight were (self-)reported at admission. REE was measured for a minimum of one hour. Total energy expenditure (TEE) was calculated by adding 10% (activity factor) above REE [26]. To achieve these goals energy expenditure (TEE) was calculated by adding 10% (activity factor) above REE [26]. Nutrition was based on TEE and total protein was aimed for at 1.5–1.7 g/kg/day but (activity factor) above REE [26].

Table 1: Enteral nutrition.

| Enteral nutrition | Energy (kcal/L) | Protein (g/L) | Glutamine (g/L) | Citrulline (g/L) | Arginine (g/L) |
|------------------|----------------|--------------|-----------------|-----------------|---------------|
| Nutrison Standard | 1000           | 40 g/L       | 4.6             | 0               | 1.6           |
| Nutrison Protein Plus | 1250        | 63 g/L       | 7.19            | 0               | 2.5           |
| Promote          | 1000           | 63 g/L       | 2.3             | 0               | 2.3           |

Table 2: Tracer dosages.

| Tracer     | Prime (µmol/kg)   | Infusate (µmol/kg/h) |
|------------|-------------------|----------------------|
| CON mean (SEM) | ALA-GLN mean (SEM) | CON mean (SEM) | ALA-GLN mean (SEM) |
| GLN M + 1  | 232.0 (13.8)      | 236.7 (8.0)         | 18.4 (1.6)      | 16.0 (1.5)        |
| CIT M + 5  | 627.2 (37.3)      | 639.8 (21.8)        | 1.2 (0.3)       | 1.0 (0.3)         |
| ARG M + 2  | 141.1 (8.4)       | 144.0 (4.9)         | 1.3 (0.1)       | 1.2 (0.1)         |

2.3. Stable Isotopes. Stable isotope tracers of L-[2-15N]-glutamine, L-[5-13C]-tracers, and L-[guanidino-15N2]-arginine were used to investigate the effect of the enteral supplementation of glutamine on the metabolism of L-glutamine, L-citrulline, and L-arginine, as well as the conversions of L-glutamine into L-citrulline and L-citrulline into L-arginine. Tracers will be noted as glutamine [M + 1], citrulline [M + 5], and arginine [M + 2], respectively. Tracers were purchased from Cambridge Stable Isotope Laboratory (Woburn, MA, USA). The Department of Clinical Pharmacy at the Erasmus Medical Center in Rotterdam, Netherlands, prepared sterile and pyrogen-free stock solutions of the tracers. The glutamine tracer was prepared 1-2 days before tracer infusion, due to the limited stability of glutamine in solution (72 h). The stock solutions were diluted with physiological saline solution minutes before the start of the tracer administration.

The tracers were administered intravenously and enterally, to study splanchnic extraction of glutamine and to distinguish between the contribution of endogenous and exogenous L-glutamine to the metabolic interrelationship between L-glutamine, L-citrulline, and L-arginine.

Tracers and amounts are listed in Table 2. Tracer dosages were calculated by using previous results from Lighthart-Melis et al. and van de Poll et al. [24, 28]. Because these studies involved surgical patients in the postabsorptive state, a pilot was performed within the first two patients to confirm steady state within our continuously enterally fed critically ill patients [29]. This resulted in a small body weight related adjustment of the priming dose.

2.4. Laboratory Analyses. Amino acid concentrations in plasma and infusates were measured using high-performance liquid chromatography, as described elsewhere [30]. Isotopic enrichment was expressed as tracer to tracee (labeled versus unlabeled substrate) ratio (TTR, %), corrected for contribution of lower masses and for background TTR (determined in the baseline sample). Glutamine, citrulline, and arginine were deproteinized plasma samples were snap-frozen in frozen carbon dioxide and stored at −80°C until assayed.
TTRs were measured by liquid chromatography-mass spectrometry [30].

2.5. Calculations. Isotopic enrichment was adjusted for natural enrichment and for the contribution of overlapping isotopomer distributions of the tracer and tracers with lower masses to the measured TTR as described by Vogt et al. [31]. Metabolic conversions were calculated using established calculations [32]. Since all tracers were administered during enteral nutrition (no matter which route of administration), adjustments were made for tracee infusion, as explained beneath in the calculations and also used by Buijs et al. [33].

For each amino acid studied, arterial enrichment curves were fitted for each patient with the use of PRISM software (version 4.03; GraphPad Software Inc., San Diego, CA). Steady state was calculated by curve fitting plateau calculations. Primarily a first-order straight line was calculated (mean minus baseline). Hereafter an exponential decay function challenged the null hypothesis (first-order straight line), when steady state was in fact more likely to have optimized (version 4.03; GraphPad Software Inc., San Diego, CA).

Steady state was calculated by curve fitting plateau calculations. Primarily a first-order straight line was calculated (mean minus baseline). Hereafter an exponential decay function challenged the null hypothesis (first-order straight line), when steady state was in fact more likely to have optimized (version 4.03; GraphPad Software Inc., San Diego, CA).

The plasma rate of appearance (WBRA: μmol kg⁻¹ h⁻¹) of glutamine, citrulline, and arginine and the known infusion rate of these tracers are based on the following equation:

\[
WBRA = \frac{I (\text{tracer})}{TTR}. \tag{1}
\]

\(I(\text{tracer})\) is the known infusion rate of the tracers and TTR is the tracer/tracee ratio. Knowing that enteral feeding and alanyl-glutamine infusion affect the RA, the WBRA calculation includes the exogenous infusion rate of tracee:

\[
WBRA = RA \text{ (endogenous)} + I (\text{tracee}). \tag{2}
\]

\(I(\text{tracee})\) reflects the exogenous amino acid (AA) supply (amino acids given by enteral nutrition):

\[
I (\text{tracee}) = I (\text{AA}) \times \frac{TTR(\text{EN})}{TTR(\text{IV})}, \tag{3}
\]

with TTR(EN) being the TTR with enterally administered tracers and TTR(IV) the TTR with intravenously administered tracers, corrected for splanchnic extraction of AA, reflected by splanchnic tracer extraction.

True RA (RA(endogenous)) is therefore calculated as follows [33]:

\[
RA \text{ (endogenous)} = \left[ \frac{I (\text{tracer})}{TTR(\text{IV})} \right] - \left[ I (\text{AA}) \times \frac{TTR(\text{EN})}{TTR(\text{IV})} \right]. \tag{4}
\]

Calculation of the rate of WB plasma turnover (\(Q: \mu \text{mol} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}\)) of glutamine into citrulline was performed by using the following equation from Castillo et al. adjusted for endogenous RA [13]:

\[
Q \text{gln} \rightarrow \text{cit} = \frac{RA \text{ (endogenous)} \times CIT_{M+1}}{TTR \text{ CIT}_{M+1} + TTR \text{ GLN}_{M+1}}, \tag{5}
\]

where WBRACIT is the plasma WBRA of citrulline, calculated from the TTR of the infused CIT M + 5 tracer by using (1), and CIT M + 1 is the CIT M + 1 coming from GLN M + 1.

Likewise, calculation of the WB plasma turnover of citrulline into arginine (de novo synthesis) was performed by using the following equation:

\[
Q \text{cit} \rightarrow \text{arg} = \frac{RA \text{ (endogenous)} \times ARG_{M+5}}{TTR \text{ CIT}_{M+5}}, \tag{6}
\]

where WBRARG is the WBRA of arginine, calculated from the TTR of ARG M + 1 by using (1), and ARG M + 5 is the ARG M + 5 coming from CIT M + 5.

Splanchnic extraction (%) of glutamine, citrulline, and arginine was calculated as follows:

\[
\left[ 1 - \left( \frac{TTR(\text{EN})}{TTR(\text{IV})} \right) \right] \times 100. \tag{7}
\]

2.6. Statistical Analyses. Data are expressed as mean ± standard error (SEM) in case of normally distributed data and as median ± interquartile range (IQR) when data were not normally distributed (tested by Shapiro-Wilk normality test). Independent sample \(t\)-test or Mann-Whitney test was used to compare control group with alanyl-glutamine group, according to distribution.

One sample \(t\)-test was used to test whether steady state of metabolic products differed from zero. Plasma values over time were compared using ANOVA and Bonferroni to determine specific time differences.

A \(p\) value of <0.05 (2-tailed) was considered as statistically significant. Statistical analysis was performed with SPSS 17.0 for Windows® (SPSS Inc., Chicago, IL, USA).

3. Results

Twenty patients were successfully included: ten received enteral alanyl-glutamine isocalorically and isonitrogenous enteral nutrition compared to 10 control patients. Results of one patient (CON) were not completely obtained due to detubation and subsequent removal of enteral tube at the last day. One patient got discharged and had his parenteral tracer administration accidentally interrupted (ALA-GLN); therefore only enteral results could be obtained. Patient characteristics are summarized in Table 3. Baseline characteristics were not significantly different when comparing the two groups.
### Table 3: Baseline characteristics.

| Baseline parameter | CON N (%)/mean (SEM)/median (IQR) | ALA-GLN N (%)/mean (SEM)/median (IQR) |
|--------------------|-----------------------------------|--------------------------------------|
| **Demographics**   |                                   |                                      |
| Sex: male/female (%) | 6/4 (60/40)                     | 6/4 (60/40)                          |
| Age (y)            | 65 (6.4)                         | 57 (5.4)                             |
| Length (cm)        | 172.6 (3.7)                      | 176.8 (3.0)                          |
| Weight (kg)        | 73.2 (5.8)                       | 777 (4.1)                            |
| BMI (kg/m²)        | 24.2 (1.0)                       | 24.5 (3.3)                           |
| **Clinical assessment** |                                |                                      |
| Type of ICU admission |                                 |                                      |
| Respiratory insufficiency | 6 (60)                       | 3 (30)                               |
| Cardiogenic shock  | 1 (10)                           | 4 (40)                               |
| Neurotrauma        | 1 (10)                           | 0                                    |
| Multitrauma        | 1 (10)                           | 2 (20)                               |
| Other              | 1 (10)                           | 1 (10)                               |
| APACHE II score    | 27.0 (2.2)                       | 25.3 (3.0)                           |
| **Laboratory measurements at inclusion** | |                                      |
| pH                 | 7.42 (0.048)                     | 7.44 (0.027)                         |
| pCO₂               | 41.4 (10.3)                      | 43.9 (9.7)                           |
| Bicarbonate (mmol/L) | 32.9 (22.0–33.0)               | 30.5 (5.3)                           |
| Glucose (mmol/L)   | 6.6 (0.83)                       | 7.5 (1.4)                            |
| Leukocytes (10⁹ /µmol/L) | 11.0 (3.1)                  | 11.8 (4.4)                           |
| Bilirubin (µmol/L) | 8.5 (5.0–16.8)                   | 9 (4.0–11.3)                         |
| Creatinine (µmol/L) | 78 (9.7)                       | 81.8 (13.7)                          |
| Urine production (mL/24 h) | 2301 (361)                | 2333 (295)                           |

#### 3.1. Nutrition

Energy expenditure was similar in both groups. All patients received 100% of the caloric target during the tracer infusions. During the whole study period 16 out of 20 received an actual nutrition of >97% of the aimed 5-day nutrition (tube feeding stopped or was lowered during the 5-day course), one patient received 89%, one 80%, one 70%, and one 66%. The last patient was eventually excluded due to unobtained steady state (described below). Mean energy intake during complete study period was 94.8% (SE 2.3) of target nutrition.

Nutrition Standard (lowest protein content) was used more often in patients in the alanyl-glutamine group, because the formula was chosen based on total amount of nitrogen (within the enteral formula) adjusted to the administered amount of alanyl-glutamine.

Although the alanyl-glutamine group received slightly more nitrogen, nitrogen per kg bodyweight was similar. Glutamine administration was as expected significantly higher in the alanyl-glutamine group. Citrulline administration was absent in both groups and total administered arginine was not different in both groups (Table 4).

#### 3.2. Glutamine, Citrulline, and Arginine Metabolism

Alanyl-glutamine was not detectable in arterial plasma in both groups. Arterial plasma concentrations of glutamine, citrulline, and arginine were not significantly different at D0 for both groups. Plasma concentrations of glutamine and arginine did not differ during the study period or between groups. Plasma concentrations of citrulline increased significantly from baseline compared to 3–4 days in the control group (D0: 28 ± 4 µmol/mL, D3: 34 ± 3.3 µmol/mL, D4: 39 ± 5.5 µmol/mL, \( p = 0.035 \)), without differences between groups.

In one patient, an isotopic steady state for glutamine, citrulline, and arginine tracers could not be reached with intravenous administration; therefore these results were excluded from analyses. This patient appeared to have higher bilirubin and creatinine levels (although not above exclusion level). Apart from this mentioned patient, steady state for the amino acid tracers could not be calculated for arginine M + 2 (EN: 1 case) and arginine M + 1 (EN: 2 cases). These results were therefore excluded from analyses as well. Steady state curves are presented in Figure S1.

TTR% for almost all infused tracers were higher when intravenously administered compared to enteral infusion, in both groups (Table 5). TTR% of infused tracers was not significantly different between control and alanyl-glutamine group. TTR% of metabolic products differed in case of citrulline M + 1 for both the intravenous and enteral experiments (Table 5).

The TTR% of the metabolic products of \([15N]glutamine\) metabolism—\([15N]citrulline\) and \([15N]arginine\)—were significantly different from zero in both groups with either way of administration. However, TTR% of the metabolic product of \([5-13C]C-4,4,5,5^2H_4\)citrulline metabolism, \([5-13C]C-4,4,5,5^2H_4\)arginine, was below detection level in 6 and 7 control patients (iv and enteral tracer administration, resp.)
Table 4: Nutrition characteristics.

| Nutrition parameter | CON mean (SEM) | ALA-GLN mean (SEM) | Sig. between groups (p) |
|---------------------|---------------|--------------------|------------------------|
| **Calorimetry**     |               |                    |                        |
| REE (kcal/24 h)     | 1847 (165)    | 1998 (85)          | 0.429                  |
| TEE (kcal/24 h)     | 1998 (165)    | 2176 (80)          | 0.350                  |
| \( \text{VCO}_2 \)  | 223 (17.0)    | 234 (10.7)         | 0.587                  |
| \( \text{VO}_2 \)  | 269 (24.8)    | 292 (12.4)         | 0.577                  |
| RQ                  | 0.84 (0.03)   | 0.81 (0.016)       | 0.237                  |
| **Nutrition**       |               |                    |                        |
| Received% of nutritional target (study period) | 3/5/2 (30/50/20) | 0/1/9 (0/10/90) |                        |
| Median (IQR)        | 98.5 (84.3;100) | 100 (98.8–100)    | 0.136                  |
| Energy (kcal/d)     | 1999 (165)    | 2190 (88)          | 0.325                  |
| Received energy (kcal/d) | 1844 (183) | 2129 (67)          | 0.170                  |
| **Nitrogen**        |               |                    |                        |
| (g/d)               | 101.5 (7.2)   | 122.7 (5.8)        | 0.034                  |
| (g/kg/d)            | 1.41 (0.08)   | 1.59 (0.11)        | 0.066                  |
| Received nitrogen   |               |                    |                        |
| (g/d)               | 93.1 (7.9)    | 119.4 (5.1)        | 0.014                  |
| (g/kg/d)            | 1.30 (0.11)   | 1.54 (0.02)        | 0.055                  |
| Received glutamine  |               |                    |                        |
| (g/d)               | 10.2 (1.0)    | 35.2 (0.17)        | (<0.000)               |
| (mmol/kg/d)         | 0.98 (0.09)   | 3.11 (0.03)        | (<0.000)               |
| Citrulline (g/d)    |               |                    |                        |
| (g/d)               | 3.6 (0.32)    | 3.2 (0.13)         | 0.278                  |
| (mmol/kg/d)         | 0.29 (0.08)   | 0.24 (0.01)        | 0.066                  |
| Baseline plasma glutamine (\(\mu\text{mol/mL}\)) | 521 (66) | 497 (37) | 0.743 |
| D3                  | 539 (21)      | 518 (34)           | 0.592                  |
| D4                  | 525 (32)      | 510 (38)           | 0.755                  |
| Baseline plasma citrulline (\(\mu\text{mol/mL}\)) | 28 (4) | 32 (3) | 0.365 |
| D3                  | 33 (3)        | 37 (2)             | 0.349                  |
| D4                  | 39 (5)        | 38 (3)             | 0.865                  |
| Baseline plasma arginine (\(\mu\text{mol/mL}\)) | 53 (6) | 72 (8) | 0.076 |
| D3                  | 64 (6)        | 62 (6)             | 0.833                  |
| D4                  | 68 (7)        | 64 (5)             | 0.645                  |

and 4 and 3 patients in the alanyl-glutamine group (iv and enteral tracer administration, resp.).

Endogenous rates of appearance were not significantly different for all administered tracers in the alanyl-glutamine group as compared to the control group (Table 5). Splanchnic extraction of glutamine and citrulline was not significantly different for both groups (Figure 2).

Whole body plasma turnover \( \text{gln} \rightarrow \text{cit} (Q; \mu\text{mol} \cdot \text{kg}^{-1} \cdot \text{h}^{-1}) \) was not significantly higher in glutamine-administered patients. In contrast, in control patients, 47.8% (±7.8) of the citrulline was derived from glutamine, versus 24.8% (±4.4; \( p = 0.018 \)) in the alanyl-glutamine group. The percentage of citrulline that served as substrate for arginine was 0% (range 0–10.8) versus 6.5% in the alanyl-glutamine group (range 1.3–12.5 ns). The percentage of glutamine that was converted into arginine was 1.3% (range 1.0–1.4) versus 0.7% (range 0.3–1.3, ns) (Table 5 and Figure 3).

4. Discussion

The primary aim of the present study was to quantify the effect of a therapeutically relevant dose of enteral L-glutamine on the synthesis of L-citrulline and subsequent L-arginine in critically ill patients receiving enteral nutrition. In contrast with our working hypothesis, we did not demonstrate a significantly higher turnover of glutamine into the substrates citrulline and arginine in this group.
### Table 5: Tracer dynamics.

| Tracer parameters and calculations | CON mean (SEM)/median (IQR) | ALA-GLN mean (SEM)/median (IQR) | Difference CON versus ALA-GLN (p) |
|-----------------------------------|-----------------------------|---------------------------------|----------------------------------|
| **Glutamine**                     |                             |                                 |                                  |
| RA GLN M + 1                      |                             |                                 |                                  |
| IV                                | 364.8 (57.5)                | 390.4 (40.0)                    | 0.720                            |
| EN                                | 787.5 (91.6)                | 606.3 (88.3)                    | 0.173                            |
| Endogenous RA GLN                 | 335.3 (62.3)                | 322.04 (39.4)                   | 0.856                            |
| TTR% GLN M + 1                    |                             |                                 |                                  |
| IV                                | 4.88 (0.38)                 | 4.88 (0.33)                     | 0.997                            |
| EN                                | 2.54 (0.35)                 | 2.44 (0.25)                     | 0.820                            |
| Splanchnic extraction GLN         | 48.2 (4.6)                  | 48.4 (3.6)                      | 0.965                            |
| **Citrulline**                    |                             |                                 |                                  |
| RA CIT M + 5                      |                             |                                 |                                  |
| IV                                |                             | 26.5 (4.7)                      | 28.5 (5.5) 0.780                 |
| EN                                | 51.7 (23.7; 69.2)           | 29.5 (20.8; 64.3)               | 0.462                            |
| Endogenous RA CIT                 | 26.5 (4.7)                  | 28.5 (5.5)                      | 0.780                            |
| TTR% CIT M + 1                    |                             |                                 |                                  |
| IV                                | 1.99 (0.33)                 | 1.13 (0.16)                     | 0.031 0.015                      |
| EN                                | 4.44 (0.47)                 | 2.64 (0.46)                     | 0.015                            |
| TTR% CIT M + 2                    |                             |                                 |                                  |
| IV                                | 0.29 (0.14)                 | 0.21 (0.08)                     | 0.622                            |
| EN                                | 1.08 (0.21)                 | 0.50 (0.19)                     | 0.057                            |
| TTR% CIT M + 5                    |                             |                                 |                                  |
| IV                                | 4.31 (0.85)                 | 4.06 (0.34)                     | 0.791                            |
| EN                                | 2.49 (2.25; 2.94)           | 1.98 (1.82; 2.29)               | 0.207                            |
| Splanchnic extraction CIT         | 33.0 (7.7)                  | 44.8 (3.1)                      | 0.185                            |
| **Arginine**                      |                             |                                 |                                  |
| RA ARG M + 2                      |                             |                                 |                                  |
| IV                                | 76.6 (12.2)                 | 75.0 (6.0)                      | 0.907                            |
| EN                                | 135.4 (106.8; 240.3)        | 121.3 (17.0)                    | 0.374                            |
| Endogenous RA ARG                 | 26.9 (25.0; 58.0)           | 31.8 (6.1)                      | 0.336                            |
| TTR% ARG M + 1                    |                             |                                 |                                  |
| IV                                | 0.44 (0.13)                 | 0.35 (0.09)                     | 0.583                            |
| EN                                | 0.97 (0.25)                 | 0.83 (0.15)                     | 0.624                            |
| TTR% ARG M + 2                    |                             |                                 |                                  |
| IV                                | 6.33 (0.76)                 | 6.00 (0.50)                     | 0.717                            |
| EN                                | 3.73 (0.78)                 | 3.26 (0.46)                     | 0.593                            |
| TTR% ARG M + 5                    |                             |                                 |                                  |
| IV                                | 0.33 (0.06)                 | 0.35 (0.07)                     | 0.898                            |
| EN                                | 0.25 (0.05)                 | 0.30 (0.05)                     | 0.500                            |
| Splanchnic extraction ARG         | 45.0 (6.2)                  | 41.8 (6.4)                      | 0.725                            |
| **Conversion rates**              |                             |                                 |                                  |
| Q Gln → Cit                       | 13.4 (4.2)                  | 6.3 (1.3)                       | 0.121                            |
| Q Cit → Arg                       | 0 (0–2.2)                   | 1.3 (0.5–3.1)                   | 0.135                            |
| Q Gln → Arg                       | 3.2 (1.0)                   | 2.4 (0.9)                       | 0.539                            |
| Q Gln → Cit% of Gln               | 4.45 (0.91)                 | 2.06 (0.42)                     | 0.026                            |
| Q Gln → Cit% of Cit               | 47.8 (7.8)                  | 24.8 (4.4)                      | 0.018                            |
| Q Cit → Arg% of Cit               | 0 (0–10.8)                  | 6.5 (1.3–12.5)                  | 0.370                            |
| Q Cit → Arg% of Arg               | 0 (0–7.4)                   | 5.3 (2.2–10.4)                  | 0.131                            |
| Q Gln → Arg% of Gln               | 1.3 (1.0–1.4)               | 0.7 (0.3–1.3)                   | 0.370                            |

RA in μmol/kg/h, endogenous RA in μmol/kg/h, splanchnic extraction in %, TTR in %, and Q in μmol/kg/h.
Glutamine is one of the most abundant amino acids in the human body. In healthy adults, the small intestine is the major organ of glutamine utilization. Enterocytes extract both arterial glutamine and in a greater extent luminal glutamine.

Intestinal glutamine degradation starts with deamination into glutamate and ammonia. Ammonia is released into the portal vein, after which it can be taken up by the liver serving ureagenesis and glutamine synthesis. Glutamate is released into the portal vein, either as glutamate, as alanine, or as \(\alpha\)-ketoglutarate after transamination with pyruvate, or it is converted to citrulline (approximately 12%, which is 60%–80% of the total citrulline) in which the amino-group and the carbon skeleton of the original glutamine molecule are preserved. The major part of this citrulline is released into the portal vein and subsequently taken up by the proximal tubular cells of the kidney for arginine de novo synthesis [22].

Citrulline itself is scarce in a regular human diet. It was first identified in the 1930s and its name is based on the juice of watermelon (\textit{Citrullus vulgaris}) [34]. In contrast to other amino acids, it is not used in protein synthesis, so it was long time considered to function solely as a metabolic intermediate, specifically in the urea cycle. However, with extensive research performed over the past decades, citrulline appears to play a considerable role in the regulation of nitrogen homeostasis and in the cardiovascular system as regulator of immunity.

After hepatic escape and renal extraction, an ammonia group from aspartate is incorporated to form arginine (catalysed by argininosuccinate synthase [ASS] and argininosuccinate lyase [ASL]) in the proximal convoluted tubules of the kidney. Citrulline is the only precursor for de novo arginine synthesis, of which the majority is executed in the kidneys. This pathway is called the “intestinal-renal axis.” The synthesized arginine from citrulline accounts for 60% of the de novo whole body arginine synthesis; however this only represents 5%–15% of the total circulating arginine [35]. This indicates that most of the plasma arginine is derived from proteolysis and food intake. This arginine pool is sufficient to provide the body’s full arginine requirements in physiological conditions.

The relationship between glutamine and arginine has been subject of research in our group since the early nineties [1, 36]. Since then, extensive research has been evolved on
using tracer methodology on this topic by us and others. Although the existence of the relationship between glutamine, arginine, and citrulline is clear, we learned that (A) mice metabolism is unequal to human metabolism [35, 37, 38], (B) enteral glutamine administration does not have the same effect as intravenous glutamine supply [23], and (C) critically ill patients behave differently as opposed to healthy volunteers [39–41]. At least three matters have remained unclear: Does postabsorptive glutamine handling differ from the postprandial state? Do critically ill patients metabolize an additional enteral dose of glutamine differently than (so far investigated) trace dosages? And do differences exist between septic and relatively stable ICU patients? We attempted to provide the answers to the first two questions. Kao et al. and Luiking et al. investigated amino acid metabolism in septic ICU patients using stable isotope methodology. Kao et al. show an altered glutamine metabolism in fasted septic patients compared to healthy volunteers [39]. With enteral administration, they show a more pronounced glutamine to citrulline conversion, as was observed earlier in non-critically ill patients [23]. Both investigators observed diminished de novo arginine synthesis. These findings strongly suggest that arginine availability is indeed at risk in septic patients [40, 42].

Since Heylands recent publication on glutamine and antioxidant supplementation in critically ill patients, concerns were raised about glutamine supplementation within their study population [10]. It has now been argued that safety is not guaranteed when high dosages (0.35 g/kg/d parenterally and 30 g/d enterally) of glutamine are administered to patients with multiple organ failure. Given the fact that liver and/or kidney failure impairs protein clearance, glutamine is probably best given to either surgical or medical critically ill patients but should not be given in case of liver or kidney failure [43, 44].

Our results could be explained by a number of considerations as follows. Primarily, the patients were well fed and not glutamine, citrulline, or arginine deficient. Therefore the use of additional glutamine may not have been as effective as within truly depleted patients.Attributing to this, most severely ill (and possibly most depleted) patients could not be included, due to the five-day study period in which dropout must be avoided.
Secondly, due to adapted nutritional formulas, control patients received an average of 10.4 grams of glutamine per day. Given the equal amounts of glutamine splanchnic extraction rates and the equal endogenous rates of appearances, the gut does not seem to metabolize glutamine differently when it comes to different amounts of enteral delivery.

The absence of glutamine promoting arginine synthesis was unexpected. In fact, control patients had a relatively larger glutamine into citrulline conversion rate (13.4 versus 6.3 μmol/kg/h) with significantly higher CIT M + 1 TTR% in the control group. Since glutamine and citrulline compete for the same transporter (neutral amino acid system N transporter: SN1), similar or more citrulline splanchnic extraction can be explained with little glutamine supply [45, 46]. Some studies have previously demonstrated the capability of the liver to take up citrulline [28]. However, this uptake was associated with a release of the liver as well, so unidirectional uptake was never demonstrated.

Unfortunately, due to study design, we were unable to provide any insight neither on hepatic versus intestinal nor on renal citrulline metabolism.

Remarkably, in our experiments, citrulline to arginine turnover and glutamine to arginine turnover were lower compared to Ligthart-Melis, with a conversion rate of 0–6.5% and 0.7–1.3%, respectively, differing with a factor of 5–10% compared to earlier experiments. Again, splanchnic extraction and enteral administration partly account for this.

Remarkably, in the control group, the median conversion of citrulline to arginine was calculated zero while having higher glutamine to arginine conversion rates. This is because the TTR% of the metabolic product of L-[5-13 C]-4,4,5,5 H4]arginine, was below detection level in most of the control patients. The glutamine to arginine production probably finds its origin in the gut by the enzymes argininosuccinate synthase and argininosuccinate lyase. Circumstantial induction seems evident since this has been subject of discussion earlier [24, 47].

Furthermore, as we know renal citrulline metabolism is autoregulated [21]: in the presence of adequate arginine concentrations, arginine de novo synthesis is diminished, whereas at low concentrations renal arginine de novo synthesis is promoted. The faith of the “unused” citrulline is unclear, but it can be used for many systems.

Most importantly, our experiments prove that excessive arginine production after glutamine supplementation does not occur; hence the safety of 0.5 g/kg/day enteral alanyl-arginine production after glutamine supplementation does not cover small metabolic changes that may have occurred in the meantime. Additionally, different metabolic phases with different energy needs are observed within this patient population [27]. The initial metabolic phase after administration was covered by the three-day administration of TEE-based nutrition with or without glutamine. Furthermore, by randomizing the administration order we attempted to outbalance potential metabolic differences. An alternative approach in which simultaneous administration through both routes is studied has the disadvantage of different tracer usage (often giving rise to different metabolic outcome) or (when given sequentially on the same day) different timing within circadian rhythm.

The study design disqualified the use of a control group, due to a five-day continuous enteral feeding regime while being immobilized to mimic minimal basal energy expenditure.

The heterogeneity of the studied population means that interpretation should be with caution. It also means that this is a reflection of the exact population that is able to receive full enteral nutrition: no instability, no bowel surgery, no sepsis, and no expected quick discharge. Therefore these results are
useful as a pilot for larger investigation on enterally enriched nutrition.

Unfortunately two patients could not fulfil their second tracer study day. This is a risk that goes hand in hand with the clinical setting. Stable isotope studies are usually performed with 5-6 patients (per group), due to complexity and expenses of the method.

In conclusion, these results prove that, in critically ill non-septic patients receiving optimal enteral nutrition including a clinically relevant dose of glutamine, the relationship between glutamine, citrulline, and arginine is still present. However in the glutamine receiving group there was no extra citrulline or arginine synthesis and splanchnic glutamine extraction was not increased. Arginine synthesis was not promoted by glutamine administration indicating that in this population glutamine supplementation is safe. This also suggests that for arginine synthesis enhancement there is no need for an additional dose of glutamine when these patients are adequately fed. Furthermore, we proved that overestimation of calculated metabolic products can be reduced by correcting for splanchnic extraction and enteral nutrition.

Abbreviations

NO: Nitric oxide
REE: Resting energy expenditure
TEE: Total energy expenditure
APACHE II: Acute Physiology and Chronic Health Evaluation II
TTR: Tracer to trace ratio
(WB)RA: (Whole body) rate of appearance
I: Infusion rate
AA: Amino acid
Q: Plasma turnover
CON: Control group
ALA-GLN: Group receiving alanyl-glutamine.

Competing Interests

Paul A. M. van Leeuwen has served as a speaker, a consultant, and an advisory board member for Fresenius Kabi. The study was partly financed by Fresenius Kabi. Other than this grant, Mechteld A. R. Vermeulen, Saskia J. H. Brinkmann, Albertus Beishuizen, Pierre M. Bet, Alexander P. J. Houdijk, and Johannes B. van Goudoever declare that there are no competing interests regarding this paper.

Authors’ Contributions

Mechteld A. R. Vermeulen designed and performed the study, performed calculations and statistical analyses, and wrote the paper. Saskia J. H. Brinkmann helped performing the study and critically reviewed the paper. Nikki Buijs critically reviewed the study; Johannes B. van Goudoever helped designing the study, performed calculations, and critically reviewed the paper. Paul A. M. van Leeuwen was responsible for all parts of the study. All authors read and approved the final paper.

Acknowledgments

The authors would like to thank Sigrid de Jong for her help with the laboratorial handling, Hans van Eijk for determining the TTRs, Erna Albers and Ingrid van den Hul for their assistance at the Intensive Care Unit, Klara Bruyn for ad hoc glutamine tracer preparation, and Gerdien Ligthart-Melis for her advice. This study was supported by a Yoshimura Grant, Norman Yoshimura Grant, 2009 and 2010, and Project “The Contribution of L-Glutamine to L-Citrulline and L-Arginine Synthesis When Alanyl-Glutamine Is Supplied in an Enteral Dose of 0.5 g/kg, in Critically Ill Patients.”

References

[1] A. P. J. Houdijk, E. R. Rijnsburger, J. Jansen et al., “Randomised trial of glutamine-enriched enteral nutrition on infectious morbidity in patients with multiple trauma,” The Lancet, vol. 352, no. 9130, pp. 772–776, 1998.
[2] P. Déchelotte, M. Hasselmann, L. Cynober et al., “L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multicenter study,” Critical Care Medicine, vol. 34, no. 3, pp. 598–604, 2006.
[3] R. D. Griffiths, K. D. Allen, F. J. Andrews, and C. Jones, “Infection, multiple organ failure, and survival in the intensive care unit: influence of glutamine-supplemented parenteral nutrition on acquired infection,” Nutrition, vol. 18, no. 7-8, pp. 546–552, 2002.
[4] Z. M. Jian, J. D. Cao, X. G. Zhu et al., “The impact of alanyl-glutamine on clinical safety, nitrogen balance, intestinal permeability, and clinical outcome in postoperative patients: a randomized, double-blind, controlled study of 120 patients,” Journal of Parenteral and Enteral Nutrition, vol. 23, no. 5, pp. S62–S66, 1999.
[5] W. Scheppach, C. Loges, P. Bartram et al., “Effect of free glutamine and alanyl-glutamine dipeptide on mucosal proliferation of the human ileum and colon,” Gastroenterology, vol. 107, no. 2, pp. 429–434, 1994.
[6] T. R. Ziegler, L. S. Young, K. Benfell et al., “Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation: a randomized, double-blind, controlled study,” Annals of Internal Medicine, vol. 116, no. 10, pp. 821–828, 1992.
[7] C. Goeters, A. Wenn, N. Mertes et al., “Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients,” Critical Care Medicine, vol. 30, no. 9, pp. 2032–2037, 2002.
[8] M. MacBurney, L. S. Young, T. R. Ziegler, and D. W. Wilmore, “A cost-evaluation of glutamine-supplemented parenteral nutrition in adult bone marrow transplant patients,” Journal of the American Dietetic Association, vol. 94, no. 11, pp. 1263–1266, 1994.
[9] B. J. Morlion, P. Stehle, P. Wachtler et al., “Total parenteral nutrition with glutamine dipeptide after major abdominal surgery: a randomized, double-blind, controlled study,” Annals of Surgery, vol. 227, no. 2, pp. 302–308, 1998.
10. D. Heyland, J. Muscedere, P. E. Wischmeyer et al., “A randomized trial of glutamine and antioxidants in critically ill patients,” *The New England Journal of Medicine*, vol. 368, no. 16, pp. 1489–1497, 2013.

11. S. N. Kaore, H. S. Amane, and N. M. Kaore, “Citrulline: pharmacological perspectives and its role as an emerging biomarker in inflammation,” *Fundamental and Clinical Pharmacology*, vol. 27, no. 1, pp. 35–50, 2013.

12. L. Castillo, M. Sanchez, J. Vogt et al., “Plasma arginine, citrulline, and ornithine kinetics in adults, with observations on nitric oxide synthesis,” *American Journal of Physiology—Endocrinology and Metabolism*, vol. 268, no. 2, pp. E360–E367, 1995.

13. L. Castillo, L. Beaumier, A. M. Ajami, and V. R. Young, “Whole body nitric oxide synthesis in healthy men determined from [15N]arginine-to-[15N]citrulline labeling,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 21, pp. 11460–11465, 1996.

14. M. F. Mulder, A. A. van Lambalgen, E. Huisman, J. J. Visser, G. C. van den Bos, and L. G. Thijss, “Protective role of NO in the regional hemodynamic changes during acute endotoxemia in rats,” *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 266, no. 4, pp. H1558–H1564, 1994.

15. J. A. Panza, P. R. Casino, D. M. Badar, and A. A. Quyyumi, “Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension,” *Circulation*, vol. 87, no. 5, pp. 1475–1481, 1993.

16. A. Barbul, S. A. Lazarou, D. T. Efron, H. L. Wasserkrug, and G. Efron, “Arginine enhances wound healing and lymphocyte immune responses in humans,” *Surgery*, vol. 108, no. 2, pp. 331–337, 1990.

17. Y. C. Luiking, M. Poeze, G. Ramsay, and N. E. P. Deutz, “The role of arginine in infection and sepsis,” *Journal of Parenteral and Enteral Nutrition*, vol. 29, no. 1, pp. S70–S74, 2005.

18. G. Bertolini, G. Iapichino, D. Radrizzani et al., “Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial,” *Intensive Care Medicine*, vol. 29, no. 5, pp. 834–840, 2003.

19. A. C. Kalil and R. L. Danner, “L-Arginine supplementation in sepsis: beneficial or harmful?” *Current Opinion in Critical Care*, vol. 12, no. 4, pp. 303–308, 2006.

20. Y. C. Luiking and N. E. P. Deutz, “Exogenous arginine in sepsis,” *Critical Care Medicine*, vol. 35, no. 9, pp. S557–S563, 2007.

21. H. A. Prins, A. P. J. Houdijk, M. J. Wiezer et al., “Reduced arginine plasma levels are the drive for arginine production by the kidney in the rat,” *Shock*, vol. 11, no. 3, pp. 199–204, 1999.

22. M. A. R. Vermeulen, M. C. G. van de Poll, G. C. Ligthart-Melis et al., “Specific amino acids in the critically ill patient—exogenous glutamine/arginine: a common denominator?” *Critical Care Medicine*, vol. 35, no. 9, pp. S568–S576, 2007.

23. G. C. Ligthart-Melis, M. C. G. van de Poll, C. H. C. Dejong, P. G. Boelens, N. E. P. Deutz, and P. A. M. van Leeuwen, “The route of administration (enteral or parenteral) affects the conversion of isotopically labeled L-[2-15N]glutamine into citrulline and arginine in humans,” *Journal of Parenteral and Enteral Nutrition*, vol. 31, no. 5, pp. 343–348, 2007.

24. G. C. Ligthart-Melis, M. C. G. van de Poll, M. A. R. Vermeulen et al., “Enteral administration of alanyl-[2-15N]glutamine contributes more to the de novo synthesis of arginine than does intravenous infusion of the dipeptide in humans,” *American Journal of Clinical Nutrition*, vol. 90, no. 1, pp. 95–105, 2009.

25. R. P. Dellinger, M. M. Levy, A. Rhodes et al., “Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock,” *Intensive Care Medicine*, vol. 39, pp. 165–228, 2013.

26. H. P. Sauerwein and R. J. M. Strack van Schijndel, “Perspective: how to evaluate studies on peri-operative nutrition? Considerations about the definition of optimal nutrition for patients and its key role in the comparison of the results of studies on nutritional intervention,” *Clinical Nutrition*, vol. 26, no. 1, pp. 154–158, 2007.

27. P. J. Weij, “Fundamental determinants of protein requirements in the ICU,” *Current Opinion in Clinical Nutrition & Metabolic Care*, vol. 17, no. 2, pp. 183–189, 2014.

28. M. C. G. van de Poll, G. C. Ligthart-Melis, P. G. Boelens, N. E. P. Deutz, P. A. M. van Leeuwen, and C. H. C. Dejong, “Intestinal and hepatic metabolism of glutamine and citrulline in humans,” *Journal of Physiology*, vol. 581, no. 2, pp. 819–827, 2007.

29. M. A. Vermeulen, “Amino acid metabolism in critically ill patients: tracer methodology in the fed and postabsorptive state,” P. A. van Leeuwen, C. H. Dejong, P. M. Bet, A. Beishuizen, N. E. Deutz, and G. C. Ligthart-Melis, Eds., 35th edition, 2011.

30. H. M. H. van Eijk, K. A. P. Wijnands, B. A. F. M. Bessem, S. W. Olde Damink, C. H. C. Dejong, and M. Poeze, “High sensitivity measurement of amino acid isotope enrichment using liquid chromatography-mass spectrometry,” *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, vol. 905, pp. 31–36, 2012.

31. J. A. Vogt, T. E. Chapman, D. A. Wagner, V. R. Young, and J. F. Burke, “Determination of the isotope enrichment of one or a mixture of two stable labelled tracers of the same compound using the complete isotopomer distribution of an ion fragment; theory and application to in vivo human tracer studies,” *Biological Mass Spectrometry*, vol. 22, no. 10, pp. 600–612, 1993.

32. R. R. Wolfe and D. L. Chinkes, “Calculations of substrate kinetics: single-pool model,” in *Isotope Tracers in Metabolic Research*, R. R. Wolfe and D. L. Chinkes, Eds., John Wiley & Sons, Hoboken, NJ, USA, 2nd edition, 2005.

33. N. Buijs, S. J. H. Brinkmann, and J. E. Oosterink et al., “Intravenous glutamine supplementation enhances renal de novo arginine synthesis in humans: a stable isotope study,” *American Journal of Clinical Nutrition*, vol. 100, no. 5, pp. 1385–1391, 2014.

34. E. Caris, I. Nicolis, C. Moinard et al., “Almost all about citrulline in mammals,” *Amino Acids*, vol. 29, no. 3, pp. 177–205, 2005.

35. G. C. Ligthart-Melis, M. C. G. van de Poll, P. G. Boelens, C. H. C. Dejong, N. E. P. Deutz, and P. A. M. van Leeuwen, “Glutamine is an important precursor for de novo synthesis of arginine in humans,” *American Journal of Clinical Nutrition*, vol. 87, no. 5, pp. 1282–1289, 2008.

36. A. P. J. Houdijk, P. A. M. van Leeuwen, T. Teerlink et al., “Glutamine-enriched enteral diet increases renal arginine production,” *Journal of Parenteral and Enteral Nutrition*, vol. 29, article E683, 2010.

37. C. Marini, I. C. Didelija, L. Castillo, and B. Lee, “Glutamine: precursor or nitrogen donor for citrulline synthesis?” *American Journal of Physiology—Endocrinology and Metabolism*, vol. 299, pp. E69–E79, 2010.
C. Kao, J. Hsu, V. Bandi, and F. Jahoor, "Alterations in glutamine metabolism and its conversion to citrulline in sepsis," *American Journal of Physiology—Endocrinology and Metabolism*, vol. 304, no. 12, pp. E1359–1364, 2013.

Y. C. Luiking, M. Poeze, G. Ramsay, and N. E. P. Deutz, "Reduced citrulline production in sepsis is related to diminished de novo arginine and nitric oxide production," *The American Journal of Clinical Nutrition*, vol. 89, no. 1, pp. 142–152, 2009.

O. Rooyackers, R. Kouchek-Zadeh, I. Tjäder, Å. Norberg, M. Klaude, and J. Wernerman, "Whole body protein turnover in critically ill patients with multiple organ failure," *Clinical Nutrition*, vol. 34, no. 1, pp. 95–100, 2015.

C. C. Kao, V. Bandi, K. K. Guntupalli, M. Wu, L. Castillo, and F. Jahoor, "Arginine, citrulline and nitric oxide metabolism in sepsis," *Clinical Science*, vol. 117, no. 1, pp. 23–30, 2009.

P. Singer, G. S. Doig, and C. Pichard, "The truth about nutrition in the ICU," *Intensive Care Medicine*, vol. 40, no. 2, pp. 252–255, 2014.

D. K. Heyland, G. Elke, D. Cook et al., "Glutamine and antioxidants in the critically ill patient: a post hoc analysis of a large-scale randomized trial," *Journal of Parenteral and Enteral Nutrition*, vol. 39, no. 4, pp. 401–409, 2015.

A. Simon, L. Plies, A. Habermeier, U. Martiné, M. Reining, and E. I. Closs, "Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells," *Circulation Research*, vol. 93, no. 9, pp. 813–820, 2003.

J. Bryk, J. B. Ochoa, M. I. T. D. Correia, V. Munera-Seeley, and P. J. Popovic, "Effect of citrulline and glutamine on nitric oxide production in RAW 264.7 cells in an arginine-depleted environment," *Journal of Parenteral and Enteral Nutrition*, vol. 32, no. 4, pp. 377–383, 2008.

R. R. van der Hulst, M. E. von Meyenfeldt, N. E. Deutz, and P. B. Soeters, "Glutamine extraction by the gut is reduced in depleted [corrected] patients with gastrointestinal cancer," *Annals of Surgery*, vol. 225, no. 1, pp. 112–121, 1997.

C. Tomlinson, M. Rafii, R. O. Ball, and P. Pencharz, "Arginine synthesis from enteral glutamine in healthy adults in the fed state," *American Journal of Physiology—Endocrinology and Metabolism*, vol. 301, no. 2, pp. E267–E273, 2011.

A. Bourriele, B. Humbert, P. Maugère, J.-P. Galmiche, and D. Darmaun, "Glutamine metabolism in Crohn's disease: a stable isotope study," *Clinical Nutrition*, vol. 23, no. 5, pp. 1167–1175, 2004.

G. C. Ligthart-Melis and N. E. P. Deutz, "Is glutamine still an important precursor of citrulline?" *American Journal of Physiology—Endocrinology and Metabolism*, vol. 301, no. 2, pp. E264–E266, 2011.